Multidrug-resistant tuberculosis

Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Easte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Disease primers Jg. 10; H. 1; S. 22
Hauptverfasser: Dheda, Keertan, Mirzayev, Fuad, Cirillo, Daniela Maria, Udwadia, Zarir, Dooley, Kelly E., Chang, Kwok-Chiu, Omar, Shaheed Vally, Reuter, Anja, Perumal, Tahlia, Horsburgh, C. Robert, Murray, Megan, Lange, Christoph
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 24.03.2024
Nature Publishing Group
Schlagworte:
692/699/255/1856
692/700
Antibiotics
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Cancer Research
Drug resistance
Epidemiology
Extensively Drug-Resistant Tuberculosis - diagnosis
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - epidemiology
Humans
Internal Medicine
Isoniazid - therapeutic use
Medical Microbiology
Medicine
Medicine & Public Health
Multidrug resistant organisms
Primer
Public health
Quality of Life Research
Rifampin - therapeutic use
Tuberculosis
Tuberculosis, Multidrug-Resistant - diagnosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
ISSN:2056-676X, 2056-676X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Eastern Europe, Russia, Asia and sub-Saharan Africa. Pre-extensively drug-resistant TB (pre-XDR-TB) refers to MDR/RR-TB that is also resistant to a fluoroquinolone, and extensively drug-resistant TB (XDR-TB) isolates are additionally resistant to other key drugs such as bedaquiline and/or linezolid. Collectively, these subgroups are referred to as drug-resistant TB (DR-TB). All forms of DR-TB can be as transmissible as rifampicin-susceptible TB; however, it is more difficult to diagnose, is associated with higher mortality and morbidity, and higher rates of post-TB lung damage. The various forms of DR-TB often consume >50% of national TB budgets despite comprising <5–10% of the total TB case-load. The past decade has seen a dramatic change in the DR-TB treatment landscape with the introduction of new diagnostics and therapeutic agents. However, there is limited guidance on understanding and managing various aspects of this complex entity, including the pathogenesis, transmission, diagnosis, management and prevention of MDR-TB and XDR-TB, especially at the primary care physician level. Multidrug-resistant tuberculosis (MDR-TB) is caused by Mycobacterium tuberculosis that is resistant to several first-line drugs. MDR-TB is an increasing public health challenge. In this Primer, Dheda et al. summarize the epidemiology and mechanisms, and discuss diagnosis, management and quality of life of patients with MDR-TB.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2056-676X
2056-676X
DOI:10.1038/s41572-024-00504-2